412 related articles for article (PubMed ID: 31214203)
1. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
Fields GB
Front Immunol; 2019; 10():1278. PubMed ID: 31214203
[TBL] [Abstract][Full Text] [Related]
2. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
Amar S; Minond D; Fields GB
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28613012
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
Chen C; Yang X; Fang H; Hou X
Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
[TBL] [Abstract][Full Text] [Related]
7. New strategies for targeting matrix metalloproteinases.
Fields GB
Matrix Biol; 2015; 44-46():239-46. PubMed ID: 25595836
[TBL] [Abstract][Full Text] [Related]
8. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.
Remacle AG; Cieplak P; Nam DH; Shiryaev SA; Ge X; Strongin AY
Oncotarget; 2017 Jan; 8(2):2781-2799. PubMed ID: 27835863
[TBL] [Abstract][Full Text] [Related]
9. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
11. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
12. Structure-Activity Relationships of UTX-121 Derivatives for the Development of Novel Matrix Metalloproteinase-2/9 Inhibitors.
Yamahana H; Komiya Y; Takino T; Endo Y; Yamada H; Asada C; Uto Y
Chem Pharm Bull (Tokyo); 2021; 69(10):1017-1028. PubMed ID: 34602570
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
14. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
15. Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
Alcantara MB; Dass CR
J Pharm Pharmacol; 2014 Jul; 66(7):895-902. PubMed ID: 24697787
[TBL] [Abstract][Full Text] [Related]
16. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies.
Amar S; Fields GB
Expert Rev Proteomics; 2015; 12(5):445-7. PubMed ID: 26174966
[TBL] [Abstract][Full Text] [Related]
18. Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities.
Ndinguri MW; Bhowmick M; Tokmina-Roszyk D; Robichaud TK; Fields GB
Molecules; 2012 Nov; 17(12):14230-48. PubMed ID: 23201642
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions.
Alford VM; Kamath A; Ren X; Kumar K; Gan Q; Awwa M; Tong M; Seeliger MA; Cao J; Ojima I; Sampson NS
ACS Chem Biol; 2017 Nov; 12(11):2788-2803. PubMed ID: 28945333
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analogues.
Bhowmick M; Stawikowska R; Tokmina-Roszyk D; Fields GB
Chembiochem; 2015 May; 16(7):1084-92. PubMed ID: 25766890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]